MUMBAI, India, June 19 -- Intellectual Property India has published a patent application (202617055929 A) filed by Texas Tech University System on May 01, 2026, for Ad36e4orf1 Peptide Fragments As Anti-Diabetic Agents.
Inventors include Dhurandhar, Nikhil, V.; and Hegde, Vijay.
The application for the patent was published on June 05, 2026, under issue no. 23/2026.
Abstract: Embodiments of the present disclosure pertain to a composition that includes at least one early gene 4 open reading frame 1 (E4orfl) peptide fragment. The E4orfl peptide fragment includes, without limitation, SEQ ID NO: 1 or a sequence with at least 65% sequence identity to SEQ ID NO: 1; SEQ ID NO: 2 or a sequence with at least 65% sequence identity to SEQ ID NO: 2; or combinations thereof. Additional embodiments of the present disclosure pertain to methods of modulating cellular glucose uptake by associating cells with a composition of the present disclosure. Further embodiments of the present disclosure pertain to methods of treating or preventing a metabolic disorder in a subject by administering a composition of the present disclosure to the subject.
Disclaimer: Curated by HT Syndication.
